Results 141 to 150 of about 4,126 (156)

Adjuvant system AS01: helping to overcome the challenges of modern vaccines

Expert Review of Vaccines, 2017
Introduction: Adjuvants are used to improve vaccine immunogenicity and efficacy by enhancing antigen presentation to antigen-specific immune cells with the aim to confer long-term protection against targeted pathogens.
Beatrice Laupeze, Arnaud Didierlaurent, Nathalie Garcon   +2 more
exaly   +2 more sources

Systematic Review of Safety of RTS,S with AS01 and AS02 Adjuvant Systems Using Data from Randomized Controlled Trials in Infants, Children, and Adults

Clinical Pharmacology: Advances and Applications, 2023
Wubetu Yihunie,1 Bekalu Kebede,1 Bantayehu Addis Tegegne,1 Melese Getachew,1 Dehnnet Abebe,1 Yibeltal Aschale,2 Habtamu Belew,2 Bereket Bahiru3 1Department of Pharmacy, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia ...
Yibeltal Aschale, Bereket Bahiru Tefera, Dehnnet Abebe   +2 more
exaly   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa

Vaccine, 2020
Otieno Walter, Seyram Kaali, Simon Kariuki   +2 more
exaly  

Marked hypotensive and blood flow-increasing effects of a new lipo-PGE (lipo-AS013) due to vascular wall targeting

Journal of Controlled Release, 2001
Mitsuko Takenaga, Rie Igarashi, Yutaka Mizushima   +2 more
exaly  

Immunogenicity and safety of the RTS,S/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: A phase IIIb, multi-center, non-inferiority, randomized, open, controlled trial

Vaccine, 2020
David Kwame Dosoo, Seyram Kaali, Lode Schuerman   +2 more
exaly  

The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination

Expert Review of Vaccines, 2016
Lode Schuerman
exaly  

Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: An open-label randomized controlled trial

Tuberculosis, 2014
Opokua Ofori-Anyinam, Patrick K. Owiafe, Olubukola T Idoko   +2 more
exaly  

Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines

Human Vaccines and Immunotherapeutics, 2014
Geert Leroux-Roels, Opokua Ofori-Anyinam, Frédéric Clement   +2 more
exaly  

Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study

Tuberculosis, 2016
Pan-chyr Yang, Opokua Ofori-Anyinam, Wei-Juin Su   +2 more
exaly